AbstractBySubCategory

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up. Suneil Jain

01

Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer. Jonathan Schoenfeld

02

High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. Abdenour Nabid

03

Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): Ten years follow-up. Thomas Wiegel

04

Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Dana Rathkopf

05

Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. Howard Scher

06

ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC). Matthew Smith

07

Long-term efficacy of stereotactic body radiotherapy for localized prostate cancer: A multi-institutional pooled analysis. Patrick Kupelian

09

Long-term survival of subjects in the prostate cancer prevention trial. Phyllis Goodman

10

Aldo-keto reductase (AKR) 1C3 as an androgen receptor coactivator. Ramesh Narayanan

100

Effect of inhibition of the PI3K/Akt/mTOR pathway on AR splicing and downstream targets. XiaoMei Liu

101

A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. Christopher Heery

102

Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer. Jong Chul Park

103

Effect of GTx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer. Evan Yu

104

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Andrew Armstrong

105

Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS). Alicia Morgans

106

Utilization and cancer detection by U.S. prostate biopsies (2005-2011). Carl Olsson

107

Activity of gemcitabine-oxalipaltin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed. Jae-Lyun Lee

108

Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy. Michael Schweizer

109

Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). Nicholas Vogelzang

11

Ex vivo prostate cancer explant organ culture model system for targeted drug development in prostate cancer Shilpa Gupta

110

Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer. Jatinder Goyal

111

Comparison of PSA slope and nadir between hypofractionated SBRT and conventionally fractionated EBRT. Mekhail Anwar

112

A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC). Ravinder Clayton

113

A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). Eric Small

114

Risk assessment for severe hypocalcemia requiring hospitalization with denosumab. Karen Autio

115

Epigenetic field effect markers as indicative of occult high-grade prostate cancer. Sandra Gaston

116

Disparities in prostate cancer treatment associated with population density of the county of residence. Clint Cary

117

Influence of ischemia on tissue androgens in eugonadal and androgen-deprived men treated with prostatectomy. Robert Montgomery

118

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. Daniel Petrylak

119

Identification of men with a genetic predisposition to prostate cancer: Targeted screening in men at higher genetic risk and controls—The IMPACT study. Ros Eeles

12

Patient-reported sexual and urinary function after open and robotic radical prostatectomy. Joseph Klink

120

Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers. Scott Tagawa

121

Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). Antoine Angelergues

122

A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. Ramachandran Venkitaraman

123

Comparision of survival rates of patients (pts) with localized prostate cancer (T1-2N0M0) treated with brachytherapy (BT) and external beam radiation therapy (EBRT): Surveillance Epidemiology and End Results (SEER) database review. Anteneh Tesfaye

124

From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). Arnoud Templeton

125

Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug–drug interaction study in patients with advanced solid tumors. Olivier Rixe

126

Stratification of risk for patients with prostate cancer at biopsy using CCP score. Neal Shore

127

Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations. Fatima Karzai

128

Rate of hot flashes in patients with advanced prostate cancer treated with GTx-758. Evan Yu

129

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE). Ian Tannock

13

Analysis of putative resistance mechanisms in recent treatments targeting the androgen receptor in castration-resistant prostate cancer (CRPC). Paul Thelen

130

Real-world experience with sipuleucel-T in patients (pts) ≥80 years old with metastatic castration-resistant prostate cancer (mCRPC): Data from PROCEED. Chadi Nabhan

131^

Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR). Anna Couvillon

132

Predictors and prognostic implication of pathologic fracture (PF), spinal cord compression (SCC), and bone surgery (BS) following diagnosis of metastatic prostate cancer (PCa). Ebere Onukwugha

133

Early response assessment and bone flare phenomenon on 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) treated with abiraterone acetate. Salvatore Luca Burgio

134

Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer. Douglas McNeel

135

Are PSA baseline levels an indicator for suitability of intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy? Ulf Tunn

136

Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). Stephane Oudard

137

Induction of endothelial proliferation and angiogenesis through activating the ERK1/2/EGF pathway mediate by CXC chemokine receptor 2 by chemokine (C-X-C motif) ligand 1. Makito Miyake

138

Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence. Judd Moul

139

Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). Oscar Goodman

14

Overtreatment of prostate cancer in Florida. Scott Gilbert

140

Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes. Nita Patel

141

A phase Ib trial of mushroom powder in biochemically recurrent, hormone-naive prostate cancer. Przemyslaw Twardowski

142

Quality-of-life outcomes for prostate cancer treatment in Australia. Jeremy Millar

143

Detection and genomic interrogation of circulating tumor cells (CTCs) and circulating tumor stem cells (CTSCs) from men with metastatic castration-resistant prostate cancer (mCRPC). Terence Friedlander

144

Dose-escalated adaptive image-guided radiotherapy versus high-dose-rate brachytherapy monotherapy for low-risk prostate cancer. Ovidiu Marina

145

Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D). Avivit Peer

146

P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC) activation. Tomasz Beer

147

Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study. Thomas Gardner

148

Location of local recurrence after MRI-guided partial prostate brachytherapy targeting only the peripheral zone: Implications for focal therapy. Konstantin Kovtun

149

Does the diagnosing urologist influence choice of initial active treatment versus observation in older men with favorable prostate cancer? Karen Hoffman

15

Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: Results of a phase I trial. David Azria

150

Gleason pattern 5 as a pathologic predictor of recurrence, development of metastasis, and prostate cancer-specific death for patients receiving salvage radiation therapy following radical prostatectomy. William Jackson

151

Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC). Christoph Reuter

152

Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Bernhard Eigl

153

Sensitivity of PTEN-deficient prostate carcinoma cells to ionizing radiation through inhibition of treatment-induced CXCL8 signaling. Chris Armstrong

154

Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. Carmel Pezaro

155

Phase II trial of combination therapy with intravenous carboplatin (C) and oral everolimus (EVE) and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trial Consortium study. Muthu Veeraputhiran

156

Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. Che-Kai Tsao

157

Multiplexed protein and gene profiling of circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) using automated immunofluorescence and fluorescence in situ hybridization. Dea Nagy

158

Is there a predictive value for measurement of tumor percentage and the number of tumor foci after prostatectomy? Reemt Hinkelammert

159

Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. Cora Sternberg

16

Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx). Daniel Keizman

160

Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate. Ayal Aizer

161

Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC). Christoph Reuter

162

Castration resistance and risk of bone metastases among men with nonmetastatic prostate cancer on androgen-deprivation therapy: A population-based cohort study from the Henry Ford Health System (HFHS) in Detroit, Michigan. Jennifer Beebe-Dimmer

163

Effect of Wnt-1 induced signaling protein-2 (Wisp-2/CCN5) on angiogenesis and invasion in prostate cancer. Yasunobu Hashimoto

164

Stereotactic body radiation therapy (SBRT) following procedures for benign prostatic hyperplasia (BPH): A report on early toxicity. Marie Gurka

165

Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. Farshid Dayyani

166

PSA doubling time of ≤6 months as the optimal cutoff for predicting clinically relevant outcomes for men receiving salvage radiation therapy post radical prostatectomy. William Jackson

167

Long-term tolerance of neoadjuvant docetaxel/estramustine chemotherapy in patients with high-risk localized prostate cancer treated at IGR in the GETUG 12 phase III trial. Pierre-Olivier Bosset

168

Use of biopsy detail to identify subgroup risk in high-risk patients with prostate cancer. Natasha Townsend

169

Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. Kurt Miller

17

Long-term outcomes of active surveillance for prostate cancer: 10 years later. David Buethe

170

Serum IGF-1 levels in men with advanced prostate cancer treated with the ERα agonist, GTx-758. Evan Yu

171

Pathologic findings in additional prostatic and periprostatic tissue removed during radical prostatectomy. Henry Chen

172

Effect of PEDF on the in vivo antitumor activities of low-dose chemotherapy in CRPC. Thomas Nelius

173

Variations in treatment modality use for the definitive management of prostate cancer in the United States. Jay Ciezki

174

Patient benefit from salvage radiation for prostate cancer. Brian Gebhardt

175

Impact of body mass index on clinicopathologic outcome and biochemical recurrence after radical prostatectomy in 1,257 Japanese patients with prostate cancer. Shintaro Narita

176

Prostate cancer (PC) follow-up and treatment by race in an equal access health system: A pilot study. Nirupama Mitikiri

177

Specification and validation of prostate cancer quality-of-care e-measures in the Veterans Health Administration (VHA). Jeremy Shelton

178

Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results. Jeanny Aragon-Ching

179

Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer. Bertrand Tombal

18

Heterogeneity of treatment effects (HTE) in stage IV prostate cancer (S4PC). Nirupama Mitikiri

180

15-year survival after radical prostatectomy (RP): Which prognostic factors are available for patient counseling? Sophie Fossa

181

Genetic instability after radiotherapy in prostate cancer: TMRSS2-ERG fusion in salvage radical prostatectomies. David Pfister

182

Wait time intervals for patients with prostate cancer in a multidisciplinary rapid diagnostic unit compared to a community-based referral pattern. Perakaa Sethukavalan

183

Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis. Douglas Jacoby

184

Prevalence of cardiovascular disease (CVD) risk factors and receipt of preventive care among prostate cancer (CaP) survivors in the United States. Kevin Pearlstein

185

Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer. Avishay Sella

186

Photoselective vaporization of the prostate compared to transurethral resection of the prostate in patients who develop prostatic obstruction following brachytherapy. Benjamin Abelson

187

11C-choline PET/CT in selection of patients for salvage cryoablation in recurrent prostate cancer. Anthonius Breeuwsma

188

Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP). Sergio Bracarda

189

Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Sten Nilsson

19

Dependence of intrafraction prostate motion within the pelvis on fraction duration during whole pelvic intensity modulated arctherapy (IMAT) versus dynamic IMRT. Nicolas Lescut

190

Beyond IGRT: Daily real time planning (RTP)—Treatment of prostate cancer, clinical implementation, and technique. James Wong

191

Trends in use of intravenous bisphosphonates in patients with prostate cancer and newly diagnosed metastases to bone in two large U.S. integrated health systems. Lois Lamerato

192

Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer. David McLeod

193

Use of microRNA signature to distinguish early from late biochemical failure in prostate cancer. Zsuzsanna Lichner

194

Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. William Oh

195

Evaluation of a genomic-based prognostic test for metastasis in high-risk post-prostatectomy patients: Does it impact physician decision making? Ketan Badani

196

A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Jorge Garcia

197

Utility of blood oxygen level dependent magnetic resonance imaging in the evaluation of tissue oxygenation patterns of prostate cancer. Bishoy Gayed

198

Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. Mark Fleming

20

Novel methodology for cost evaluation of anticancer drugs in castrate-resistant prostate cancer. Helmy Guirgis

200

Stability of white blood cell counts following standard radiation approaches for high-risk adenocarcinoma of the prostate: Implications for combination therapy. Steven Finkelstein

201

Impact of magnetic resonance imaging (MRI) in the local staging, risk group classification, and treatment of patients with prostate cancer with combination of high dose rate (HDR) brachytherapy and external beam radiotherapy (EBRT). Alfonso Gomez-Iturriaga

202

Health services utilization differences between patients with metastatic (M1) and nonmetastatic (M0) prostate cancer (PCa). Candice Yong

203

Certificate of need and use of IMRT in elderly patients with low-risk prostate cancer. Grace Lu-Yao

204

G-CSF utilization during abiraterone acetate (AA) and cabazitaxel (C) therapy: A retrospective U.S. claims analysis. Maneesha Mehra

205

Efficacy and toxicity of q 2 weeks versus weekly versus q 3 weeks docetaxel in metastatic castration-resistant prostate cancer (CRPC). Akshiv Malhotra

206

Current status and outcomes of salvage radiotherapy for patients with PSA recurrence after prostatectomy: A JROSG surveillance study. Takashi Mizowaki

207

Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials. Orazio Caffo

208

A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD). Evan Yu

209

Effect of dutasteride on tumor proliferation during the regrowth phase of intermittent androgen ablation therapy in men with advanced prostate cancer. Daniel Shevrin

21

Time to follow-up and treatment in patients with newly diagnosed prostate cancer (PC) across clinical stages in an equal access health system. Anitha Nallu

210

Who dies from prostate cancer in a Western country? A multicenter analysis. Yohann Loriot

211

C35: A new prognostic tool and potential target in prostate cancer. Deepak Kilari

212

High-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of rectal bleeding. Shinji Kariya

213

Effect of simultaneous blockade of androgen and estrogen receptors on prostate cancer: In vivo study. Rafael Nunez-Nateras

214

Diagnostic accuracy of PET scan in salvage lymph node resections in patients with prostate cancer (CaP). David Pfister

215

Role for IL2 adjunctive cotherapy for suppression of a solid tumor with designer T cells: Phase I trial data in prostate cancer. Richard Junghans

216

Comparative effective analysis between enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer. Akhil Chopra

217

Salvage brachytherapy for prostate bed recurrence following radical prostatectomy. Kristin Smith

218

A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). Michael Schweizer

219

Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data. Charles Ryan

22

Patient-reported quality of life in men with TURP undergoing proton therapy for prostate cancer. Derek Lee

220

Arachidonic acid drives amoeboid transendothelial invasion through ligand independent activation of EphA2. Mick Brown

221

Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer. Evan Yu

222

Is routine prostate biopsy needed prior to radical cystectomy? Yasuhiro Hashimoto

223

Cabazitaxel in patients with metastatic castrate-resistant prostate cancer previously treated with a docetaxel-containing regimen: A single U.K. cancer center's experience using Early Access Programme and Cancer Drugs Fund. Claire Kelly

224

Incidental prostate cancer in patients with radical cystectomy for bladder cancer. Hooman Djaladat

225

Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB). Deepak Kilari

226

A novel method for decreasing rectal toxicity during prostate radiotherapy by prostate-rectum separation: An evaluation of irradiation dose parameters and acute side effects. Michael Mathers

227

Cell-free DNA as a prognostic marker for response to taxan-based chemotherapy in patients with prostate cancer (CaP). Alexandra Kienel

228

Potential cost-effectiveness of a diagnostic that identifies localized versus metastatic prostate cancer in men with biochemical recurrence after radical prostatectomy. Mark Bensink

229

Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). Matt Galsky

23

Phase II trial of acai juice product in biochemically recurrent prostate cancer. Elizabeth Kessler

230

Utilization of local salvage therapy after primary radiotherapy for prostate cancer. Henry Tran

231

Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. Konstantin Kovtun

232

The use of electromagnetic transponder beacons to reduce planning target volume (PTV) margins in post-prostatectomy patients undergoing adjuvant or salvage radiation therapy. Madeera Kathpal

233

Postdocetaxel treatment for castrate-resistant prostate cancer: The sequential use of abiraterone and cabazitaxe. David Fackrell

234

Metabolite assay and histology on exactly the same tissue. Dean Troyer

235

Experimental therapy of PC-3 and DU-145 human androgen-independent prostate cancers with targeted cytotoxic analog of somatostatin an-162. Ferenc Rick

236

Testosterone kinetics after proton therapy for low- and intermediate-risk prostate cancer. Romaine Nichols

237

Relationship of overall survival and the frequency of performing transrectal ultrasound-guided biopsy of the prostate in those patients with low-risk tumors electing active surveillance. David Buethe

238

Generation of virtual control groups for single-arm prostate cancer (PCa) adjuvant trials. Zhenyu Jia

239

A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed. Susan Halabi

24

Age at diagnosis and treatment for prostate cancer (PC) in two distinct integrated health care systems. Deanna Cross

240

PSA outcomes in patients with adenocarcinoma of the prostate with presenting PSA > 20 ng/ml. Daniel Shasha

241

The effects of age, stage, treatment, and Charlson comorbidity index (CCI) on quality of life after prostate cancer diagnosis in a single cohort. Deanna Cross

242

Rectal dose-volume differences for scanning proton beam therapy with or without an endorectal balloon for the treatment of prostate cancer. Anand Desai

243

The risk of debilitating falls in Manitobans living with prostate cancer (pc). Joel Gingerich

244

Biochemical and functional outcomes of brachytherapy for young men (≤50) with prostate cancer. Daniel Shasha

245

Impact of the USPSTF D recommendation: Early assessment of referrals for elevated PSA and prostate biopsies in a LUGPA following statement revision. Kathleen McGinley

25

Identification of prognostic groups in patients with hormone-sensitive metastatic prostate cancer at the present time: An analysis of the GETUG 15 phase III trial. Gwenaelle Gravis

26

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). Matthew Smith

27

The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). Caroline Pratz

28

Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer. Elena Castro

29

Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED. A. Sartor

30^

Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC). Michael Morris

31

Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. Jessica Strock

33

Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC). Emmanuel Antonarakis

34

A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during IMRT for prostate cancer: Analysis of dosimetric outcomes. Danny Song

35

Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy. Mercedeh Ghadessi

36

Adjuvant versus neoadjuvant androgen deprivation with radiation therapy for prostate cancer: Does sequencing matter? Michael Weller

37

Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451). Elisabeth Heath

38

Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery. William Sohn

39

Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment. Mehmet Hepgur

40

First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors. Test Name

41

Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists. Peter Albertsen

42

The molecular relationship among concurrent prostate cancer foci. David VanderWeele

43

The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study. Robert van Soest

44

Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC). Daniel Danila

45

Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy. Stephen Freedland

47

ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). Dana Rathkopf

48

Mortality following hip fractures in men with prostate cancer. Mieke Van Hemelrijck

49

PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease. Hong Zhang

50

A gene expression signature to predicit overall, prostate cancer, and non–prostate cancer survival. Chunde Li

51

Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy. Ashley Ross

52

Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. Romain Mathieu

53

Evaluation of the UCSF cancer of the prostate risk assessment for prediction of biochemical recurrence (CAPRA) to predict which patients need dose escalation in intermediate-risk disease. Daniel Taussky

54

Multidisciplinary care and management of very low-risk prostate cancer. Ayal Aizer

55

Image guidance for post-prostatectomy radiotherapy: Are we missing the mark? Noah Kalman

56

Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. James Gulley

57

Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. Paul Corn

58

A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. Daniel Petrylak

59

A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort. Matthew Cooperberg

60

Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer. Sumit Subudhi

61

Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC). Elizabeth Punnoose

62

Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study. Mark Fleming

63

Evaluating the hypothalamic-pituitary-adrenal axis (HPAA) in men receiving ketoconazole for castrate-resistant prostate cancer (CRPC). Rahul Aggarwal

64

ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data. Karim Fizazi

65^

Association of radical prostate cancer therapy with a survival benefit in the older man. Paul Cathcart

66

Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. Michael Brawer

67

Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials. E. Crawford

68

Sentinel lymph node in prostate carcinoma: Methodology, feasibility, surgical, and oncological consequences: A prospective study about 93 patients. Claude Soler

69

Prior cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate cancer specific and all-cause mortality. Kristina Mirabeau-Beale

70

Severe lack of comprehension of common prostate health terminology in underserved populations: External validation. Viraj Master

71

Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). Susan Slovin

72

Quantifying the ki-67 heterogeneity profile in prostate cancer. Mitchell Kamrava

73

Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. Eric Small

74

Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC). Manish Kohli

75

Feasibility of RNA sequencing to detect TMPRSS2:ERG fusions following laser capture microdissection of prostate cancer. Won Kim

76

Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC). Robert Zielinski

77

Maximum tumor diameter as a predictor for outcome following salvage radiation for prostate cancer. Skyler Johnson

78

Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Ian Schnadig

79

Genomic analysis of prostate cancer. Christine Barnett

80

Relationship of oral glycine with radiation-induced HIF1-alpha and tumor growth delay in a prostate cancer xenograft. Elizabeth Kessler

81

Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. Neil Martin

82

Intermediate versus short-course hormone therapy and mortality in men with high-risk prostate cancer treated with radiation therapy. Akash Nanda

83

Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry. Matthew Stenmark

84

Safety profile of poxviral vaccines: NCI experience. Joseph Kim

85

Importance of Gleason score on 18F-choline PET/CT findings in patients with biochemical relapse of prostate cancer disease (PSA<1.0 ng/ml). Marina Hodolic

86

Association of cross-talk between α1D-adrenergic receptor (α1D -AR) and transient receptor potential vanilloid 1 (TRPV1) with the proliferation of PC3 prostate cancer cells. Giorgio Santoni

87

Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS). James Brooks

88

Is there a withdrawal syndrome with abiraterone acetate (AA)? Laurence Albiges

89

Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial. Orazio Caffo

90

Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279). Amit Bahl

91

Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer. Matthew Cooperberg

92

Long-term health-related quality of life in patients treated for localized prostate cancer. Sanoj Punnen

93

Effect of generation 2.5 antisense inhibitor of androgen receptor on MDV3100-resistant prostate cancer cell growth in vitro and in vivo. Yoshiaki Yamamoto

94

Prediction of risk for prostate cancer in histopathologically negative biopsies by multigene epigenetic assay. Leander Van Neste

95

Phase I trial of total androgen blockade, weekly docetaxel, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Stephen Ramey

96

Pretreatment serum biomarkers and clinical outcome in the phase II trial of zibotentan (endothelin A receptor antagonist) in metastatic CRPC. Julia Shelkey

97

Racial differences in survival outcomes among men with localized prostate cancer. Grace Lu-Yao

98

Hemi salvage HIFU in patients with radio recurrent prostate cancer: Early experience and results. Gilles Pasticier

99

Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. John Araujo

LBA8